Articles by Rachel Lutz - Page 11

Latest Articles

Multiple Sclerosis Drug Could Be Effective Target for Parkinson's Disease Treatment
  |  Rachel Lutz
Dimethylfumarate, a multiple sclerosis drug metabolite, could be a safe and effective therapy for Parkinson’s disease and slow its onset.
Fasting Cycle Could Reduce Multiple Sclerosis Symptoms
  |  Rachel Lutz
Following a diet that mirrors the habits of fasting can reduce the symptoms of multiple sclerosis.
Alleviating Multiple Sclerosis Symptoms Possible with Yoga and Aquatic Exercises
  |  Rachel Lutz
Multiple sclerosis symptoms such as fatigue, depression, and paresthesia can be alleviated using yoga and aquatic exercises.
Pulmonary Rehabilitation Programs Should Reach More Patients
  |  Rachel Lutz
Pulmonary rehabilitation programs could help more patients with respiratory conditions like severe asthma and chronic obstructive pulmonary disease (COPD), but they are not used widely enough.
Multiple Sclerosis Drug Possibly Linked to Colorectal and Breast Cancer
  |  Rachel Lutz
The multiple sclerosis immunosuppressant drug mitoxantrone might be linked to an increased risk for breast and colorectal cancer.
Well-Controlled Bleeding with rVIII-SingleChain
  |  Rachel Lutz
Researchers reported that adults and adolescents with hemophilia A had well controlled bleeding when dosed two or three times weekly with recombinant factor VIII single chain (rVIII-SingleChain).
Two Grants Awarded to Medical College of Wisconsin Researcher
  |  Rachel Lutz
Researchers discovered a clinically translatable gene therapy protocol, which is a gene delivery system that introduced the production of therapeutic clotting proteins in platelets, so that the inhibition of inactivating antibodies is avoided.
FDA Approval Updates for Hemophilia Drugs
  |  Rachel Lutz
Over the past few months, the Food and Drug Administration (FDA) approved several drugs for the control and prevention of bleeding episodes in patients with hemophilia. Other drug classifications granted included Orphan Drug Status and Breakthrough Therapy designation.
Breaking Ground in Two Hemophilia Drug Construction Plants
  |  Rachel Lutz
Two new hemophilia drug plant construction plans were initiated over the summer by separate manufacturers, headlines said.

Most Popular

@MDMagazine

$vacMongoViewPlus$ $vAR$